Publications
Search our bibliography using the filters on the right-hand side.
Displaying 401 through 450 of 750 publications.
Skip to main content
Foley P, Sherif B, Mallya UG, Fox T, Gottlieb AB. Secukinumab treatment sustains patient-reported outcome benefits through 1 year. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(Suppl 2):56.
Collins A, Hawe E, Vickers A, Mallya UG, McBride D, Capkun-Niggli G, Olson M, Thorlund K. Secukinumab 300 mg demonstrates higher probability of efficacy than other biologics in psoriasis: indirect comparison. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia.
Sinclair R, McLeod L, Mallya UG, Fox T, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(S2):68.
Wilson M, Mody R, Ursan I, Carr S. The budgetary impact of vedolizumab in the management of moderately to severely active ulcerative colitis and Crohn's disease in the United States. Poster presented at the 2015 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 7, 2015. San Diego, CA. [abstract] J Manag Care Pharm. 21(4a):S57.
Patel J, Coleman A, Wilson M, McDade C, Carr S, Earnshaw S. Budgetary impact on a U.S. health plan after adopting umeclidinium/vilanterol (UMEC/VI) for the management of moderate-to-severe COPD. Poster presented at the 2015 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 7, 2015. San Diego, CA. [abstract] J Manag Care Pharm. 2015 Apr 7; 21(4a):S55.
Zhou X, Wang J, Zhang J, Copley-Merriman C, Torigoe Y, Reyes C, Seymour JF, Offner FC, Trneny M, Salles GA. Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. Hematology. 2015 Apr;129(36). doi: 10.1179/1607845414Y.0000000179
Chang J, Odom DM, Radder CN, Kappeler C, Xu R, Qin S, Kim T, Li J. A post-hoc health-related quality of life (HRQoL) analysis of patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial. Poster presented at the 2015 Gastrointestinal Cancers Symposium; January 15, 2015. San Francisco, CA.
Herring WL, Grant TJ, Mladsi DM. A mathematical model to estimate the health benefits and costs of diabetic retinopathy screening programs. Presented at the 2015 Institute for Operations Research and Management Science Computing Conference; January 12, 2015. Richmond, VA.
Mauskopf JA, Mitchell SE, Samuel M. Estimating costs in a cost-effectiveness analysis: adherence to HTA guidance. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam.
Graham CN, Hechmati G, Hjelmgren J, de Liege F, Knoof A, Lanier J, Knox HN, Barber B, de Pouvourville G. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type ras metastatic colorectal cancer. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam.
Graham CN, Hechmati G, Hjelmgren J, de Liege F, Lanier J, Knox H, Barber B. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer. 2014 Nov;50(16):2791-801. doi: 10.1016/j.ejca.2014.08.016
Rosseli D, Rueda J, Wolowacz SE, Brockbank JA, Abeysinghe SS. Cost-effectiveness of dabigatran compared with warfarin, apixaban, rivaroxaban and low molecular weight heparins for the treatment and secondary prevention of venous thromboembolism in Colombia. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands.
McLeod LD, Mallya UG, Fox T, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the 23rd European Academy of Dermatology and Venereology Congress; October 8, 2014.
Sherif BN, Mallya UG, Fox T, Gottlieb AB. Secukinumab treatment sustains patient-reported outcome benefits through 1 year. Poster presented at the 23rd European Academy of Dermatology and Venereology Congress; October 8, 2014.
Lebwohl M, Mordin MM, Mallya UG, Gnanasakthy A, Fox T. Secukinumab treatment provides fast relief from patient-reported psoriasis burden. Poster presented at the 23rd European Academy of Dermatology and Venereology Congress; October 2, 2014. Amsterdam, The Netherlands.
Laramee P, Brodtkorb TH, Rahnali N, Knight C, Barbosa C, Francois C, Toumi M, Daeppen JB, Rehm J. The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model. BMJ Open. 2014 Sep 16;4(9). doi: 10.1136/bmjopen-2014-005376
Wheeler SB, Kuo TM, Goyal RK, Meyer AM, Hassmiller Lich K, Gillen EM, Tyree S, Lewis CL, Crutchfield TM, Martens CE, Tangka F, Richardson LC, Pignone MP. Regional variation in colorectal cancer testing and geographic availability of care in a publicly insured population. Health Place. 2014 Jul 23;29C:114-23. doi: 10.1016/j.healthplace.2014.07.001
Wilkins E, Fisher M, Brogan AJ, Talbird SE. An analysis of cost and health outcomes associated with tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the United Kingdom. Poster presented at the 20th International AIDS Conference; July 20, 2014.
Chirila C, Ziemiecki RM, Davenport EK, Kaschinski D, Pfarr E, Palencia R. Health-related quality-of-life analysis for patients with type 2 diabetes mellitus treated with empagliflozin. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014.
Copley-Merriman C, Zelt S, Stone G, Barrows SM, Mordin MM, Hogue SL. Emerging-market payer needs: how should these countries be included in dermatology drug development plans? Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014.
Kamat SA, Blanchette C, Wilson MR, Tangirala M, Earnshaw SR, Offord S, Gutierrez B, Eramo A, Baker RA. Healthcare cost savings associated with aripiprazole once-monthly (AOM) treatment among schizophrenia patients with psychiatric hospitalizations prior to AOM treatment initiation. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 3, 2014.
Wilkins E, Fisher M, Brogan AJ, Talbird SE. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naive adults with HIV-1 infection in the United Kingdom. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014. [abstract] Value Health. 2014 May; 17(3):A276.
Ramamohan V, Mladsi DM, Kaye JA, Boey W, Pozzi R. An outcomes model for high-risk non-muscle-invasive bladder cancer treatment options. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 2, 2014. Montreal, Canada. [abstract] Value Health. 2014 May; 17(3):A87.
Purser MF, Wilson MR, Mladsi DM, Wu Y. Literature review of economic models for the treatment of parkinson's disease. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 2, 2014. Montreal, Canada. [abstract] Value Health. 2014 May; 17(3):A60. doi: 10.1016/j.jval.2014.03.355
Nabhan C, Byrtek M, Dawson KL, Zhou X, Ziemiecki RM, Zelenetz AD, Friedberg JW, Cerhan JR, Flowers CR. Differences in disease characteristics, treatment patterns, and outcomes between men (M) and women (W) with follicular lymphoma (FL): prospective evaluation of 2650 US patients (pts). Poster presented at the ASCO; May 2014.
Brogan AJ, Talbird SE, Thompson JR, Miller JD, Rubin J, Deniz B. Cost-effectiveness of telaprevir combination therapy for chronic hepatitis C. PLoS One. 2014 Mar 6;9(3):e90295. doi: 10.1371/journal.pone.0090295
Davis A, Mehrotra S, Holl J, Daskin MS. Nurse staffing under demand uncertainty to reduce costs and enhance patient safety. Asia Pac J Oper. 2014 Feb;31(1):1-19. doi: 10.1142/S0217595914500055
Martin P, Byrtek M, Dawson K, Ziemiecki RM, Friedberg JW, Cerhan JR, Flowers CR, Link BK. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National Lymphocare Study. Cancer. 2013 Dec 1;119(23):4129-36. doi: 10.1002/cncr.28350
Davis AE, Mehrotra S, Friedewald J, Ladner D. Characteristics of a simulation model of the national kidney transplantation system. Poster presented at the 2013 Winter Simulation Conference: Simulation: Making Decisions in a Complex World; December 2013. [abstract] Ieee/Acm Trans Comput Biol Bioinform. 2013 Dec; p.2320-9.
Earnshaw SR, McDade CL, Graham CN, Spears J, Kessler C. Economic comparison of treating hemophilia patients who have developed inhibitors via immune tolerance induction versus prophylaxis and on-demand treatment with bypassing agents. Poster presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2013. New Orleans, LA. [abstract] Blood. 2013 Nov 15; 122(21):422. doi: 10.1182/blood.V122.21.422.422
Graham CN, Knox HN, Winfree KB, Hess LM, Liu J, Ortuzar WF. Cost-minimization analysis of pemetrexed/carboplatin with maintenance pemetrexed (PemC) versus paclitaxel/carboplatin/bevacizumab with maintenance bevacizumab (PCB) in nonsquamous non-small cell lung cancer (NS-NSCLC). Poster presented at the Quality Care Symposium of the American Society of Clinical Oncology; November 2013.
Brennan VK, Talbird SE, Beard SM, Brogan AJ, Flanagan D, Delpech V, Bosanquet N, Fisher M. The public health and economic impact from earlier diagnosis and earlier antiretroviral treatment of HIV in the UK. Poster presented at the 14th European AIDS Conference/EACS; October 16, 2013.
Messiah SE, Lopez-Mitnik G, Winegar D, Sherif BN, Arheart KL, Reichard KW, Michalsky MP, Lipshultz SE, Miller TL, Livingstone AS, de la Cruz-Muñoz N. Effect of ethnicity on weight loss among adolescents 1 year after bariatric surgery. World J Diabetes. 2013 Oct 15;4(5):202-9. doi: 10.4239/wjd.v4.i5.202
Yardley DA, Hortobagyi GN, Lebrun F, Beck JT, Neven P, Baselga J, Ziemiecki RM. Patient-reported physical, emotional, and social functioning in advanced breast cancer: insights from BOLERO-2. Poster presented at the Breast Cancer Symposium; September 7, 2013. San Francisco, United States. Previously presented at the American Society of Clinical Oncology.
Mauskopf J, Chirila C, Graham J, Gersten ID, Leather H, Maziarz RT, Baden LR, Bolanos-Meade J, Brown JMY, Walsh TJ, Horowitz MH, Kurtzberg J, Marr KA, Wingard JR. Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. Am J Health Syst Pharm. 2013 Sep;70(17):1518-27.
Mladsi DM, Ronquest NA, Tannus G, Fonseca M, Saag K. Estimated cost effectiveness of lower-dose submicron diclofenac compared with traditional diclofenac in Brazil. Poster presented at the 2013 ISPOR 4th Latin America Conference; September 2013. Buenos Aires, Argentina. [abstract] Value Health. 2013 Sep; 16(7):PA717-8. doi: 10.1016/j.jval.2013.08.2226
Hahn KA, Wise LA, Riis AH, Mikkelsen EM, Rothman KJ, Banholzer K, Hatch EE. Correlates of menstrual cycle characteristics among nulliparous Danish women. Clin Epidemiol. 2013 Aug 19;5(1):311-9.
Odom DM, Talbird SE, Brogan AJ, Schenkel B. A meta-analysis of randomized, controlled trials of ustekinumab and adalimumab for moderate-to-severe psoriasis. Poster presented at the Summer Meeting of the American Academy of Dermatology; August 2013.
Brogan A, Talbird S, Thompson J, Kim Y, Olson J, Peterson J, Piontkowsky D, Pietrandoni G. Budget impact of the introduction of elvitegravir/cobicistat/emtricitabine/tenofovir, the first integrase inhibitor-based single-tablet antiretroviral regimen for HIV treatment, to US third-party payers. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2, 2013. Dublin, Ireland. [abstract] Value Health. 2013 Aug; 16(7):A343-4.
Cohen CJ, Meyers JL, Davis KL. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV. BMJ Open. 2013 Aug 1;3(8):e003028.
Brown TM, Holland J, Bokowy KL, Horblyuk R. Can transformational programs aimed at improving hospital management, leadership, and productivity systems affect financial performance? J Hospital Admin. 2013 Jul 30;2(4):111-9.
Harrison CN, Mesa RA, Kiladjian J-J, Al-Ali H-K, Gisslinger H, Knoops L, Squier M, Sirulnik A, Mendelson E, Zhou X, Copley-Merriman C, Hunter DS, Levy RS, Cervantes F, Passamonti F, Barbui T, Barosi G, Vannucchi AM. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol. 2013 Jul;162(2):229-39. doi: 10.1111/bjh.12375
Yardley DA, Hortobagyi GN, Lebrun F, Beck JT, Neven P, Baselga J, Ziemiecki RM. Patient-reported physical, emotional, and social functioning in advanced breast cancer: insights from BOLERO-2. Poster presented at the American Society of Clinical Oncology; June 2013.
Wood WA, Whitley J, Goyal RK, Brown PM, Sharf A, Irons R, Rao KV, Essenmacher A, Serody JS, Coghill JM, Armistead PM, Sarantopoulos S, Gabriel DA, Shea TC. Effectiveness of etoposide chemomobilization in lymphoma patients undergoing auto-SCT. Bone Marrow Transplant. 2013 Jun;48(6):771-6. doi: 10.1038/bmt.2012.216
Davis AE, Mehrotra S, Friedewald J, Ladner D. Predicting long run geographic disparities in kidney transplantation via fluid approximations. Poster presented at the Institute for Operations Research and Management Science (INFORMS) Healthcare Conference; June 2013.
Davis KL, Mody R, Rubin DT, Wang E. Association between suboptimal therapy and health care costs in inflammatory bowel disease. Poster presented at the 2013 Digestive Disease Week; May 2013.
Herring WL, Mladsi D, Mauskopf J. Patient-level simulation modeling for economic evaluations: opportunities and challenges in a practical setting. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 1, 2013. New Orleans, LA. [abstract] Value Health. 2013 May; 16(3):A28-9.
Herring WL, Mladsi DM, Miles L, Ronquest N. A novel approach to ranking parameter uncertainty in one-way sensitivity analysis: what tornado diagrams are missing. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 1, 2013. New Orleans, LA. [abstract] Value Health. 2013 May; 16(3):A20.
Ronquest N, Mladsi D, Hopley C, Edgell E. The economic value of an innovative knee implant system for total knee arthroplasty. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 6, 2013. New Orleans, LA. [abstract] Value Health. 2013 May; 16(3):A225.
Davis AE, Mehrotra S, McElroy L. Implications of statewide sharing on geographic disparity in kidney transplantation in the US. Poster presented at the American Transplant Congress; May 2013.